3F AORTIC BIOPROSTHETIC HEART VALVE
Report
- Report Number
- 2025587-2017-00670
- Event Type
- Injury
- Date Received
- April 25, 2017
- Date of Event
- April 5, 2017
- Report Date
- April 9, 2017
- Manufacturer
- MEDTRONIC 3F THERAPEUTICS, INC.
- Product Code
- LWR
- PMA / PMN Number
- P060025
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- GM
- Reporter Occupation
- PHYSICIAN
Narratives
TITLE: INITIAL EXPERIENCE WITH AORTIC VALVE REPLACEMENT VIA A MINIMALLY INVASIVE APPROACH: A COMPARISON OF STENTED, STENTLESS AND SUTURELESS VALVES CITATION: MEDICAL SCIENCE MONITOR (2017) 23:1645-1654 (DOI 10.12659/MSM.901780) AUTHORS: KONERTZ, JOHANNA ET AL. EARLIEST DATE OF E-PUBLISH/PUBLISH USED FOR EVENT DATE. NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT CANNOT BE DETERMINED WHETHER THIS EVENT HAS BEEN PREVIOUSLY REPORTED. (B)(4).
IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
MEDTRONIC RECEIVED INFORMATION VIA LITERATURE REVIEW REGARDING THE RESULTS AFTER MINIMALLY INVASIVE STENTED, STENTLESS AND SUTURELESS VALVE. ALL DATA WERE COLLECTED FROM A SINGLE CENTER BETWEEN JANUARY 2010 AND JUNE 2015. THE STUDY POPULATION INCLUDED 79 PATIENTS, 27 OF WHICH WERE IMPLANTED WITH A MEDTRONIC 3F SURGICAL VALVE. THE PATIENTS IMPLANTED WITH THE MEDTRONIC DEVICE WERE PREDOMINANTLY MALE WITH A MEDIAN AGE OF 71.1 YEARS. SERIAL NUMBERS WERE NOT PROVIDED. AMONG ALL PATIENTS IMPLANTED WITH A 3F VALVE, ADVERSE EVENTS INCLUDED: ATRIAL FIBRILLATION (AFIB) TREATED WITH MEDICATION, ELECTROCARDIOGRAM (ECG) CHANGES TREATED WITH A PERMANENT PACEMAKER IMPLANT, INCREASED GRADIENT MEASUREMENTS, MILD REGURGITATION AND BLEEDING TREATED WITH RE-EXPLORATION. NO ADDITIONAL ADVERSE PATIENT EFFECTS WERE REPORTED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 301909 | 3F AORTIC BIOPROSTHETIC HEART VALVE | HEART-VALVE, NON-ALLOGRAFT TISSUE | LWR | MEDTRONIC 3F THERAPEUTICS, INC. | 1000 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 71 YR | Required Intervention |